Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(18)32756-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Simplified Approach to Managing Newly Diagnosed Patients with Mild-to-Moderate Hypertension in Routine Clinical Practice.
Adv Ther
December 2024
Global Medical and Patient Affairs, Servier, Suresnes, France.
Introduction: The aim of the observational SIMPLE study was to assess real-life effectiveness and safety of a single-pill combination (SPC) of perindopril arginine/amlodipine in a broad range of subjects with newly diagnosed mild-to-moderate hypertension treated in Canadian general practice.
Methods: Treatment-naïve participants aged 18-65 years with mild-to-moderate hypertension, whose physicians decided to initiate the perindopril/amlodipine SPC, were recruited from Canadian clinical practice from October 2017 to February 2019. Participants were followed at 3- (M3) and 6-month (M6) visits after treatment initiation.
Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease.
Adv Ther
December 2024
GSK, US Value Evidence and Outcomes, Collegeville, PA, 19426-0989, USA.
Introduction: Chronic obstructive pulmonary disease (COPD) is associated with exacerbations which can reduce quality of life and increase mortality. Single-inhaler triple therapy (SITT) is recommended for maintenance treatment of COPD among patients experiencing exacerbations despite dual-therapy use. This real-world comparative effectiveness study compared the impact of SITTs, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), and budesonide/glycopyrrolate/formoterol fumarate (BUD/GLY/FORM), on COPD exacerbations and mortality.
View Article and Find Full Text PDFEnrolment characteristics in age-related macular degeneration clinical trials: a cross-sectional study.
Eye (Lond)
December 2024
Department of Ophthalmology and Vision Science, University of Toronto, Suite 400, 340 College Street, Toronto, ON, M5T 3A9, Canada.
Background/objectives: To investigate demographic enrolment characteristics in age-related macular degeneration (AMD) trials.
Subjects/methods: Clinicaltrials.gov was searched with "age-related macular degeneration" to identify RCTs with double, triple, or quadruple masking.
Loss of Hoxa5 function affects Hox gene expression in different biological contexts.
Sci Rep
December 2024
Centre de Recherche sur le Cancer de L'Université Laval, Centre de Recherche du CHU de Québec-Université Laval (Oncology), 1401, 18e Rue, Québec, QC, G1J 1Z4, Canada.
Hoxa5 plays numerous roles in development, but its downstream molecular effects are mostly unknown. We applied bulk RNA-seq assays to characterize the transcriptional impact of the loss of Hoxa5 gene function in seven different biological contexts, including developing respiratory and musculoskeletal tissues that present phenotypes in Hoxa5 mouse mutants. This global analysis revealed few common transcriptional changes, suggesting that HOXA5 acts mainly via the regulation of context-specific effectors.
View Article and Find Full Text PDFOutdoor nitrogen dioxide exposure and longitudinal health status trajectory in the Canadian National Population Health Survey.
Sci Rep
December 2024
Environmental Health Science and Research Bureau, Health Canada, Vancouver, BC, Canada, Ottawa, ON, Canada.
Few studies have examined the association between air pollution and the trajectory of global health status measures related to the functional impacts of chronic disease. To address this gap, we examined the trajectory of the Health Utilities Index (HUI) over 17 years of follow-up among Canadian National Population Health Survey (NPHS) participants. Annual average nitrogen dioxide (NO) exposures from a national land use regression surface were mapped to 15,631 NPHS participants at their place of residence provided at each follow-up.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!